Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; 3 of the 41 sources its claims cite were checked for support.
Abstract
Omega-3 fatty acids (FAs) reduce postprandial triacylglycerol (TG) concentrations. This study was undertaken to determine whether this effect was due to reduced production or increased clearance of chylomicrons. Healthy subjects (n = 33) began with a 4-week, olive oil placebo (4 g/d) run-in period. After a 4-week wash-out period, subjects were randomized to supplementation with 4 g/d of ethyl esters of either safflower oil (SAF), eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA) for 4 weeks. Results for EPA and DHA were similar, and therefore the data were combined into one omega-3 FA group. Omega-3 FA supplementation reduced the postprandial TG and apolipoprotein B (apo B)-48 and apoB-100 concentrations by 16% (P = 0.08), 28% (P < 0.001), and 24% (P < 0.01), respectively. Chylomicron TG half-lives in the fed state were reduced after omega-3 FA treatment (6.0 +/- 0.5 vs. 5.1 +/- 0.4 min; P < 0.05), but not after SAF (6.9 +/- 0.7 vs. 7.1 +/- 0.7 min). Omega-3 FA supplementation decreased chylomicron particle sizes (mean diameter; 293 +/- 44 vs. 175 +/- 25 nm; P < 0.01) and increased preheparin lipoprotein lipase (LPL; 0.6 +/- 0.1 vs. 0.9 +/- 0.1 micromol/h/ml; P < 0.05) activity during the fed state, but had no effect on postheparin LPL or hepatic lipase activities. The results suggest that omega-3 FA supplementation accelerates chylomicron TG clearance by increasing LPL activity, and that EPA and DHA are equally effective.
Overview
CoChat Summary
TL;DR
In healthy adults, 4 weeks of EPA or DHA supplementation accelerated fed-state chylomicron triglyceride clearance and increased preheparin lipoprotein lipase activity, with EPA and DHA showing similar effects. The authors conclude that omega-3 fatty acids reduce postprandial lipemia mainly by increasing LPL-mediated chylomicron TG clearance rather than by reducing chylomicron production.
Key findings
Omega-3 supplementation reduced postprandial TG, apoB-48, and apoB-100 concentrations by 16% (P = 0.08), 28% (P < 0.001), and 24% (P < 0.01), respectively. Fed-state chylomicron TG half-lives were shorter after omega-3 treatment (6.0 ± 0.5 vs. 5.1 ± 0.4 min; P < 0.05) but not after safflower oil (6.9 ± 0.7 vs. 7.1 ± 0.7 min); fasting half-lives were unaffected. Chylomicron mean diameter decreased (293 ± 44 vs. 175 ± 25 nm; P < 0.01), and fed-state preheparin LPL activity increased (0.6 ± 0.1 vs. 0.9 ± 0.1; P < 0.05; units as reported), while postheparin LPL and hepatic lipase activities did not change significantly. EPA and DHA results were similar and were combined into one omega-3 group.
Methods
Randomized, double-blind, parallel-group, placebo-controlled study in 33 healthy subjects (11 per group: safflower oil, EPA, or DHA). After a 4-week olive oil placebo run-in and 4-week wash-out, subjects received 4 g/d ethyl esters of safflower oil, EPA, or DHA for 4 weeks. Outcomes included oral fat tolerance tests, intravenous fat clearance tests using a [3H]triolein-labeled lipid emulsion, heparin tests for lipase activity, and ANCOVA controlling for baseline values.
Limitations
The paper states that non-LPL-mediated clearance by tissues such as spleen, muscle, adipose tissue, or kidney cannot be excluded, and that it cannot rule out the possibility that omega-3 supplementation caused the intestine to secrete smaller chylomicrons. It also notes that the mechanism responsible for increased LPL activity requires further investigation. Evident from the text: the sample was small (n = 33 total, 11 per group), participants were healthy/normolipidemic, and the intervention was short (4 weeks), which limits generalizability to hypertriglyceridemic or clinical populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 6 Clearance curves of [ 3 H]triolein-labeled lipid emulsion from chylomicron fraction measured during the fed state (each point is the average of three tests administered at 5, 6, and 7 h of constant feeding). Subject numbers and symbols as in Fig. 2.](https://figures.cochat.ai/paper-figures/cd451e75949d4761b42e05d951fde193/omega-3-fatty-acid-supplementation-accelerates-chylomicron-triglyceride-figure-6.png)


Verification
Claims the paper makes
1 Valid · 0 Not valid · 20 Not checked · 48 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant effect of treatment on fasting plasma TG, and total, HDL, LDL, and VLDL-C concentration (Table 2).”
- Also stated in: § DISCUSSION · plain
“Consistent with this finding, -3 fatty acids did not reduce fasting TG concentrations.”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > Fasting lipid profile
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Preheparin LPL activities during the fed state increased after DHA (47%; P Ͻ 0.05) and EPA (73%; P Ͻ 0.05) treatments compared with SAF, but no change was de-tected in the fasting state (Fig. 8).”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > Lipase activities
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Preheparin LPL activities during the fed state increased after DHA (47%; P Ͻ 0.05) and EPA (73%; P Ͻ 0.05) treatments compared with SAF”
- Also stated in: § Abstract · plain
“increased preheparin lipoprotein lipase (LPL; 0.6 ؎ 0.1 vs. 0.9 ؎ 0.1 mol/h/ml; P Ͻ 0.05) activity during the fed state”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > Lipase activities
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Omega-3 FA supplementation reduced the postprandial TG and apolipoprotein B (apo B)-48 and apoB-100 concentrations by 16% ( P ؍ 0.08), 28% ( P Ͻ 0.001), and 24% ( P Ͻ 0.01), respectively.”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Chylomicron PL concentrations were not significantly different before and after treatments, but chylomicron TG tended to be reduced by EPA and DHA.”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > Chylomicron size
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 69 claims and to verify the 38 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fish oil (omega-3 fatty acids) lowers post-prandial triglyceride levels by 16% to 40% in a dose-dependent fashion, in part by upregulating lipoprotein lipase activity and accelerating the clearance of chylomicrons (30).”
From Dietary Strategies for Improving Post-Prandial Glucose, Lipids, Inflammation, and Cardiovascular Health (2008) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Comparing pre-heparin and post-heparin LPL activity showed consistently increased pre-heparin activity, while post-heparin activity was unchanged by OM3FA treatment in most studies [38, 39, 43] but not all [41].”
From Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review (2017) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“Pre-heparin LPL activity increased following both DHA and EPA treatment [38]”
In the citing paper
“Lowered postprandial TG levels are also explained by increased chylomicron clearance.”
In the citing paper
“Both EPA and DHA treatment significantly increased removal of TGs in chylomicrons in the fed state but not in the fasted state.”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > DISCUSSION
“Fish oil supplementation has been shown to decrease the PL-TG ratio in the chylomicron particles, indicating reduced chylomicron size (9).This was observed in the present study”
§ Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance > DISCUSSION
“| EPA | 0.8 Ϯ 0.2 | 0.8 Ϯ 0.1 | 18.2 Ϯ 4.2 | 10.0 Ϯ 2.4 | 319 Ϯ 53 | 149 Ϯ 20 a |”
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“Plasma was analyzed for total cholesterol, TG, and HDL-C concentrations using a Cobas Fara II with enzymatic reagents from Boehringer Mannheim; VLDL and LDL-C concentrations were estimated by the Friedewald equation (20).”
MethodMarkwell, M. A. K., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90586-9 · Cited by 6,458 · cited 1×
“1 mg protein/mg TG) and then adjusted to 1 mg/ml with sample buffer (23).”
MethodFish oils and plasma lipid and lipoprotein metabolism in humans: a critical review
Harris, W. S. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38310-3 · Cited by 1,127
Self-citationSuppression by diets rich in fish oil of very low density lipoprotein production in man.
Nestel, P. J., Connor, W. E., Reardon, M. F., Connor, S., Wong, S., & Boston, R. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111422 · Cited by 616
Mori, T. A., Burke, V., Puddey, I. B., Watts, G. F., O’Neal, D. N., Best, J. D., & Beilin, L. J. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1085 · Cited by 588
Fatty acid modulation of endothelial activation
De Caterina, R., Liao, J. K., & Libby, P. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.1.213s · Cited by 486
Brunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484 · cited 2×
“Chylomicrons (48) and lipid emulsions (49) are cleared more slowly in patients with elevated VLDL concentrations (likely because of increased competition for LPL), and reductions in endogenous VLDL concentrations accelerate chylomicron clearance (50).”
BackgroundPostprandial lipoproteins and progression of coronary atherosclerosis
Karpe, F., Steiner, G., Uffelman, K., Olivecrona, T., & Hamsten, A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90085-x · Cited by 483
Goodfellow, J., Bellamy, M. F., Ramsey, M. W., Jones, C. J. H., & Lewis, M. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00548-3 · Cited by 380
Weintraub, M. S., Zechner, R., Brown, A., Eisenberg, S., & Breslow, J. L. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113806 · Cited by 331 · cited 2×
“nature of the fat in the test meal (6, 8, 11, 12, 28, 29).”
BackgroundReduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids
Harris, W. S., Connor, W. E., Alam, N., & Illingworth, D. R. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38424-8 · Cited by 321 · cited 3×
“nature of the fat in the test meal (6, 8, 11, 12, 28, 29).”
BackgroundSelf-citationActivation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308 · cited 1×
“Since PPAR� has been shown to increase LPL activity via a direct transcriptional effect on the LPL promoter ( 75 ), this mechanism may at least partly explain the increased LPL activity observed with � -3 fatty acids.”
BackgroundGrimsgaard, S., Bonaa, K., Hansen, J., & Nordøy, A. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.3.649 · Cited by 300
n‐3 fatty acids and lipoproteins: Comparison of results from human and animal studies
Harris, W. S. (1996) · Lipids · doi:10.1007/bf02529870 · Cited by 264
Self-citationSchneeman, B. O., Kotite, L., Todd, K. M., & Havel, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2069 · Cited by 255 · cited 1×
“2 ml) prepared from 6 ml plasma were delipidated with 12 ml of ethanol-ether (3:1, v/v) overnight (22).”
MethodChylomicron clearance in normal and hyperlipidemic man
Grundy, S. M., & Mok, H. Y. I. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80006-6 · Cited by 218 · cited 1×
“] Chylomicrons (48) and lipid emulsions (49) are cleared more slowly in patients with elevated VLDL concentrations (likely because of increased competition for LPL), and reductions in endogenous VLDL concentrations accelerate chylomicron clearance (50).”
BackgroundTriglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia.
Sanders, T. A., Sullivan, D. R., Reeve, J., & Thompson, G. R. (1985) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.5.5.459 · Cited by 212
Effects of fish oil on VLDL triglyceride kinetics in humans
Harris, W., Connor, W., Illingworth, D., Rothrock, D., & Foster, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42339-9 · Cited by 211
Self-citationWillumsen, N., Hexeberg, S., Skorve, J., Lundquist, M., & Berge, R. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41315-x · Cited by 201
Blomhoff, R., Helgerud, P., Rasmussen, M., Berg, T., & Norum, K. R. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.23.7326 · Cited by 190 · cited 1×
“The possibility that fish oil enhances non-LPL-mediated clearance by tissues such as spleen, muscle, adipose tissue, or kidney cannot be excluded, however (16, 33 ).”
BackgroundAlaupovic, P., Mack, W. J., Knight-Gibson, C., & Hodis, H. N. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.715 · Cited by 184
Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans.
Chin, J. P., Gust, A. P., Nestel, P. J., & Dart, A. M. (1993) · Hypertension · doi:10.1161/01.hyp.21.1.22 · Cited by 154
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans
Rambjør, G. S., W»len, A. I., Windsor, S. L., & Harris, W. S. (1996) · Lipids · doi:10.1007/bf02637050 · Cited by 147
Self-citationKhan, S., Minihane, A.-M., Talmud, P. J., Wright, J. W., Murphy, M. C., Williams, C. M., & Griffin, B. A. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30473-9 · Cited by 145
Sharrett, A. R., Chambless, L. E., Heiss, G., Paton, C. C., & Patsch, W. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.12.2122 · Cited by 143
Lipoprotein lipases, lipoproteins and tissue lipids in rats fed fish oil or coconut oil
Haug, A., & Høstmark, A. T. (1987) · The Journal of Nutrition · doi:10.1093/jn/117.6.1011 · Cited by 140 · cited 1×
“in fasting plasma from humans (11–14, 43), rats (44), chickens (45), or pigs (46).”
BackgroundEicosapentaenoic Acid Induces mRNA Expression of Peroxisome Proliferator‐Activated Receptor γ
Chambrier, C., Bastard, J., Rieusset, J., Chevillotte, E., Bonnefont‐Rousselot, D., Therond, P., Hainque, B., Riou, J., Laville, M., & Vidal, H. (2002) · Obesity Research · doi:10.1038/oby.2002.70 · Cited by 139 · cited 1×
“(74) reported that adipose tissue mRNA levels for this transcription factor were positively correlated with plasma EPA concentrations.”
BackgroundPanarotto, D., Rémillard, P., Bouffard, L., & Maheux, P. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00945.x · Cited by 137 · cited 1×
“LPL is known to be stimulated in the fed state (64), presumably by insulin (65, 66).”
BackgroundInfluence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases
Harris, W., Lu, G., Rambjør, G., Wõlen, A., Ontko, J., Cheng, Q., & Windsor, S. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.2.254 · Cited by 135 · cited 2×
“However, we (15) reported that fish oil increased preheparin LPL activities of fasting”
BackgroundSelf-citationBaginsky, M. L., & Brown, W. V. (1979) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40610-8 · Cited by 110
KOBATAKE, Y., KURODA, K., JINNOUCHI, H., NISHIDE, E., & INNAMI, S. (1984) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.30.357 · Cited by 110
α-Linolenic, Eicosapentaenoic and Docosahexaenoic Acids Affect Lipid Metabolism Differently in Rats
Ikeda, I., Wakamatsu, K., Inayoshi, A., Imaizumi, K., Sugano, M., & Yazawa, K. (1994) · Journal of Nutrition · doi:10.1093/jn/124.10.1898 · Cited by 106
Harris, W., & Muzio, F. (1993) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/58.1.68 · Cited by 105 · cited 3×
“However, in a previous study from our lab, the clearance of Intralipid (20%; 8 g of fat injected in the fasting state) was unaltered by fish oil supplementation despite a 24% reduction in fasting TG concentrations (9).”
BackgroundSelf-citationKarpe, F., Hellénius, M.-L., & Hamsten, A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90076-8 · Cited by 102
Lovegrove, J. A., Brooks, C. N., Murphy, M. C., Gould, B. J., & Williams, C. M. (1997) · British Journal of Nutrition · doi:10.1079/bjn19970142 · Cited by 97
The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance.
Harris, W. S., & CONNOR, W. E. (1980) · PubMed · Cited by 96
Self-citationNelson, G. J., Schmidt, P. C., Bartolini, G. L., Kelley, D. S., & Kyle, D. (1997) · Lipids · doi:10.1007/s11745-997-0146-5 · Cited by 92 · cited 1×
“On the other hand, a hypotriglyceridemic effect of DHA has been reported in healthy subjects (59) and in patients with combined hyperlipidemic (60).”
BackgroundWong, S. H., Fisher, E. A., & Marsh, J. B. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.6.836 · Cited by 91 · cited 2×
“oils slow hepatic VLDL production rate (34–37) and reduce apoB-100 secretion from HepG2 cells (38).”
BackgroundHansen, J., Grimsgaard, S., Nilsen, H., Nordøy, A., & Bønaa, K. H. (1998) · Lipids · doi:10.1007/s11745-998-0188-8 · Cited by 91
Brunzell, J. D., Porte, D., & Bierman, E. L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90089-1 · Cited by 86 · cited 1×
“Although it is possible that reduced postprandial competition from hepatic particles played a role in the enhanced chylomicron TG clearance, this seems unlikely for two reasons: 1) at plasma TG concentrations below 200 mg/dl, LPL is not saturated (51, 52), and 2) LPL prefers chylomicrons over VLDL as substrates (53).”
BackgroundPeripheral triacylglycerol extraction in the fasting and post-prandial states
Potts, J. L., Fisher, R. M., Humphreys, S. M., Coppack, S. W., Gibbons, G. F., & Frayn, K. N. (1991) · Clinical Science · doi:10.1042/cs0810621 · Cited by 84 · cited 1×
“Although it is possible that reduced postprandial competition from hepatic particles played a role in the enhanced chylomicron TG clearance, this seems unlikely for two reasons: 1) at plasma TG concentrations below 200 mg/dl, LPL is not saturated (51, 52), and 2) LPL prefers chylomicrons over VLDL as substrates (53).”
BackgroundWilliams, C. M., Moore, F., Morgan, L., & Wright, J. (1992) · British Journal of Nutrition · doi:10.1079/bjn19920123 · Cited by 81 · cited 1×
“nature of the fat in the test meal (6, 8, 11, 12, 28, 29).”
The absorption and transport of lipids by the small intestine
Tso, P., & Fujimoto, K. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90145-a · Cited by 78 · cited 1×
“(40), not the monoacylglycerol pathway that predominates in enterocytes postprandially (41) so the CaCo-2 findings may not reflect normal physiology.”
BackgroundFish oils in hypertriglyceridemia: a dose-response study
Harris, W., Rothrock, D. W., Fanning, A., Inkeles, S. B., Sh, G., Illingworth, D. R., & CONNOR, W. E. (1990) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.3.399 · Cited by 78
Self-citationFatty acid esterification during differentiation of the human intestinal cell line Caco-2
Trotter, P. J., & Storch, J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82166-4 · Cited by 75 · cited 1×
“(40), not the monoacylglycerol pathway that predominates in enterocytes postprandially (41) so the CaCo-2 findings may not reflect normal physiology.”
BackgroundQuantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins
Kotite, L., Bergeron, N., & Havel, R. J. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40071-9 · Cited by 75
Size and lipid composition of chylomicrons of different Svedberg units of flotation
Fraser, R. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43018-4 · Cited by 74
Splanchnic and overall cardiovascular hemodynamics during eating and digestion.
Cc, C. (1983) · PubMed · Cited by 72
Davidson, M. H., Maki, K. C., Kalkowski, J., Schaefer, E. J., Torri, S. A., & Drennan, K. B. (1997) · Journal of the American College of Nutrition · doi:10.1080/07315724.1997.10718680 · Cited by 68 · cited 1×
“On the other hand, a hypotriglyceridemic effect of DHA has been reported in healthy subjects (59) and in patients with combined hyperlipidemic (60).”
BackgroundNozaki, S., Garg, A., Vega, G., & Grundy, S. M. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/53.3.638 · Cited by 67
Lu, G., Windsor, S. L., & Harris, W. S. (1999) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(98)00094-1 · Cited by 65 · cited 1×
“3 rotor for 2 h at 100,000 rpm in a Beckman TL-100 ultracentrifuge (21).”
MethodSelf-citationN-3 fatty acids and chylomicron metabolism in the rat
Harris, W. S., Hustvedt, B. E., Hagen, E., Green, M. H., Lu, G., & Drevon, C. A. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37258-8 · Cited by 64
Self-citationEicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil
Wojenski, C. M., Silver, M. J., & Walker, J. (1991) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(91)90246-e · Cited by 63 · cited 1×
“EPA was reported to be primarily responsible for the hypotriglyceridemic effect of -3 fatty acids in vitro (38), in rats (54–56), and in humans (57).”
BackgroundDietary fish oil decreases VLDL production rates
Daggy, B., Arost, C., & Bensadoun, A. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90107-x · Cited by 61 · cited 1×
“in fasting plasma from humans (11–14, 43), rats (44), chickens (45), or pigs (46).”
BackgroundRössner, S., Boberg, J., Carlson, L. A., FREYSCHUSS, U., Lassers, B. W., & Rössner, S. (1974) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1974.tb00380.x · Cited by 60 · cited 1×
“] Chylomicrons (48) and lipid emulsions (49) are cleared more slowly in patients with elevated VLDL concentrations (likely because of increased competition for LPL), and reductions in endogenous VLDL concentrations accelerate chylomicron clearance (50).”
BackgroundModerate fish oil intake improves lipemic response to a standard fat meal: A study in 25 healthy men
Brown, A. J., & Roberts, D. C. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.3.457 · Cited by 59 · cited 1×
“nature of the fat in the test meal (6, 8, 11, 12, 28, 29).”
Bordin, P., Bodamer, O. A., Venkatesan, S., Gray, R., Pa, B., & Halliday, D. (1998) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600522 · Cited by 58
Effect of eicosapentaenoic acid on triacylglycerol transport in CaCo-2 cells
Murthy, S., Albright, E., Mathur, S. N., & Field, F. J. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90144-m · Cited by 54 · cited 1×
“cells (39), it is not unreasonable to hypothesize that -3”
BackgroundRegional changes in adipose tissue blood flow and metabolism in rats after a meal
West, D. B., Prinz, W. A., & Greenwood, M. R. (1989) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1989.257.4.r711 · Cited by 52
Diurnal variation in lipoprotein lipase activity
Arasaradnam, M., Morgan, L., Wright, J., & Gama, R. (2002) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/0004563021901883 · Cited by 49 · cited 1×
“LPL is known to be stimulated in the fed state (64), presumably by insulin (65, 66).”
BackgroundIkeda, I., Kumamaru, J., Nakatani, N., Sakono, M., Murota, I., & Imaizumi, K. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.4.1159 · Cited by 46 · cited 1×
“Indeed, fat absorption was not reduced (30, 31) and chylomicron lipids were”
BackgroundCartwright, I. J., & Higgins, J. A. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34902-6 · Cited by 43
Fat feeding decreases insulin responsiveness of adipose tissue lipoprotein lipase
Sadur, C. N., Yost, T. J., & Eckel, R. H. (1984) · Metabolism · doi:10.1016/0026-0495(84)90235-x · Cited by 35 · cited 1×
“can be modified by the presence of dietary fats (67); thus”
BackgroundHarris, W. S., Windsor, S. L., & Caspermeyer, J. J. (1993) · The Journal of Nutritional Biochemistry · doi:10.1016/0955-2863(93)90111-9 · Cited by 35
Self-citationHuff, M. W., Telford, D. E., Edmonds, B. W., McDonald, C. G., & Evans, A. J. (1993) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(93)90056-f · Cited by 34 · cited 1×
“in fasting plasma from humans (11–14, 43), rats (44), chickens (45), or pigs (46).”
BackgroundA new method for the study of chylomicron kinetics in vivo
Park, Y., Grellner, W. J., Harris, W. S., & Miles, J. M. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.6.e1258 · Cited by 34 · cited 7×
“Plasma (2 ml) was layered below 8 ml of distilled water and spun in a SW41 rotor for 30 min at 25,000 rpm in a Beckman L7-65 ultracentrifuge as previously described (18, 19).”
BackgroundMethodInfluentialSelf-citationMassion, C. G., & McNeely, M. (1973) · Clinical Chemistry · doi:10.1093/clinchem/19.5.499 · Cited by 30
Simple, reproducible procedure for selective measurement of lipoprotein lipase and hepatic lipase.
Blache, D., Bouthillier, D., & Davignon, J. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.1.154 · Cited by 29 · cited 1×
“The blank contained 50 mg of NaCl and no SDS to inhibit lipase activity (25, 26).”
BackgroundMeasurement of human chylomicron triglyceride clearance with a labeled commercial lipid emulsion
Park, Y., Damron, B. D., Miles, J. M., & Harris, W. S. (2001) · Lipids · doi:10.1007/s11745-001-0696-6 · Cited by 28 · cited 6×
“Plasma (2 ml) was layered below 8 ml of distilled water and spun in a SW41 rotor for 30 min at 25,000 rpm in a Beckman L7-65 ultracentrifuge as previously described (18, 19).”
BackgroundMethodInfluentialSelf-citationvan Barlingen, H. H. J. J., Kock, L. A. W., de Man, F. H. A. F., Erkelens, D. W., & de Bruin, T. W. A. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05703-x · Cited by 22 · cited 1×
“Although it is possible that reduced postprandial competition from hepatic particles played a role in the enhanced chylomicron TG clearance, this seems unlikely for two reasons: 1) at plasma TG concentrations below 200 mg/dl, LPL is not saturated (51, 52), and 2) LPL prefers chylomicrons over VLDL as substrates (53).”
BackgroundHerzberg, G. R., Chernenko, G. A., Barrowman, J. A., Kean, K. T., & Keough, K. M. W. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90097-f · Cited by 21 · cited 1×
“Indeed, fat absorption was not reduced (30, 31) and chylomicron lipids were”
BackgroundDesager, J. P., Dricot, J., & Harvengt, C. (1989) · PubMed · Cited by 18
Disturbances in dietary fat metabolism and their role in the development of atherosclerosis
Weintraub, M. S., Charach, G., & Grosskopf, I. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)88046-8 · Cited by 16
Pehowich, D. J. (1998) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(98)90040-0 · Cited by 12
Research works printed but not linked: 1
- 8. Harris, W. S., and S. L. Windsor. 1991. N-3 fatty acid supplements reduce chylomicron levels in healthy volunteers. J. Appl. Nutr. 43: 5-15.
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
Self-citationEffects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B., Chew, P., & Lau, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.012 · Cited by 732
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives
Harris, W. S., Miller, M., Tighe, A. P., Davidson, M. H., & Schaefer, E. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.008 · Cited by 552
Self-citation
Metadata
- Authors
- Park, Y., & Harris, W. S.
- Affiliations
- Saint Luke's Hospital (US)
- Corresponding author
- Harris, William S.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2003-03
- Volume
- 44
- Issue
- 3
- Pages
- 455-463
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2028676438
- Cited by
- 348
- References
- 77
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 14 · 2022: 17 · 2021: 17 · 2020: 16 · 2019: 13 · 2018: 14 · 2017: 12 · 2016: 16 · 2015: 19 · 2014: 13 · 2013: 23 · 2012: 10
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6382 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Heart Association
- National Institutes of Health (5r01hl047468-04)
- National Heart, Lung, and Blood Institute (HL-47468)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- omega-3 fatty acids, postprandial triglycerides, eicosapentaenoic acid, docosahexaenoic acid, apolipoprotein B-48, apolipoprotein B-100, lipoprotein lipase, hepatic lipase
- MeSH terms
- Administration, Oral, Adult, Aged, Apolipoproteins B, Cholesterol, Chylomicrons, Double-Blind Method, Fasting, Fat Emulsions, Intravenous, Female, Half-Life, Heparin, Humans, Lipoprotein Lipase, Male, Metabolic Clearance Rate, Middle Aged, Safflower Oil, Triglycerides, Fatty Acids, Omega-3, Postprandial Period, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.